^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EPHA7 mutation

    i
    Other names: EPHA7, EPH Receptor A7, HEK11, Ephrin Type-A Receptor 7, EPH Homology Kinase 3, EPH-Like Kinase 11, EHK3, EK11, Receptor Protein-Tyrosine Kinase HEK11, Tyrosine-Protein Kinase Receptor EHK-3, Eph Homology Kinase-3
    Entrez ID:
    2045
    over2years
    Malignant Pediatric Melanocytic Tumor with Novel MED15::ATF1 Fusion (ASDP 2023)
    Thus, treatment based on a clear cell sarcoma protocol was suggested. Treatment with nivolumab and ipilimumab had already been initiated due to a working diagnosis of melanoma; only limited clinical follow-up is available to date.
    Clinical • PD(L)-1 Biomarker
    |
    BRAF (B-raf proto-oncogene) • BAP1 (BRCA1 Associated Protein 1) • EWSR1 (EWS RNA Binding Protein 1) • SOX10 (SRY-Box 10) • FUS (FUS RNA Binding Protein) • PRAME (Preferentially Expressed Antigen In Melanoma) • TP63 (Tumor protein 63) • ATF1 (Activating Transcription Factor 1) • EPHA7 (EPH Receptor A7) • CRTC1 (CREB Regulated Transcription Coactivator 1)
    |
    BRAF V600E • EPHA7 mutation
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    over3years
    Molecular Landscape and Prognostic Biomarker Analysis of Advanced Pancreatic Cancer and Predictors of Treatment Efficacy of AG Chemotherapy. (PubMed, Front Oncol)
    The purpose of this study is to further investigate molecular alterations in locally advanced pancreatic cancer and identify predictors of the efficacy of nab-paclitaxel plus gemcitabine (AG) chemotherapy. CDKN2B, FAT3, MTAP, and SMAD4 may be biomarkers that distinguish primary tumors from metastases. EPHA7 mutation may serve as a prognostic biomarker to predict the treatment efficacy of AG chemotherapy in locally advanced pancreatic cancer.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NOTCH1 (Notch 1) • CCNE1 (Cyclin E1) • MTAP (Methylthioadenosine Phosphorylase) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • RNF43 (Ring Finger Protein 43) • SMAD4 (SMAD family member 4) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • CARD11 (Caspase Recruitment Domain Family Member 11) • FAT3 (FAT Atypical Cadherin 3) • GATA6 (GATA Binding Protein 6) • HMGA2 (High mobility group AT-hook 2) • EPHA7 (EPH Receptor A7) • ACVR2A (Activin A Receptor Type 2A)
    |
    KRAS mutation • RNF43 mutation • EPHA7 mutation
    |
    gemcitabine • albumin-bound paclitaxel
    over4years
    [VIRTUAL] The predictive values of EPHA3 mutations for response to immune checkpoint inhibitors in solid tumors (ESMO 2021)
    Our data indicated that EPHA3 mutations were associated with prolonged OS in NSCLC, rather than other cancer types, suggesting that it might act as a predictive biomarker for ICIs therapy in NSCLC. EPHA3 mutations were also correlated with higher TMB and increased activated natural killer cells in NSCLC.
    Checkpoint inhibition • Tumor Mutational Burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • EPHA3 (EPH receptor A3) • EPHA5 (EPH Receptor A5) • EPHA7 (EPH Receptor A7)
    |
    PD-L1 expression • TMB-H • MSI-H/dMMR • EPHA3 mutation • EPHA7 mutation